North America Pharmacogenomics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (PCR, Sequencing, Microarray, Gel Electrophoresis, Mass Spectrometry, and Others), Application (Drug Discovery, Oncology, Neurology and Psychiatry, Pain Management, Cardiovascular Diseases, and Others), and End User (Hospitals and Clinics, Biopharmaceutical Companies, CROs and CDMOs, and Others)
The North America pharmacogenomics market is expected to reach US$ 6,534.83 million by 2028 from US$ 3,333.43 million in 2021. it is estimated to grow at a CAGR of 10.1% from 2021 to 2028.
The key factors driving the growth of this market are the increasing prevalence of chronic diseases, the surge in demand for precision medicines, and the rise in funding for pharmacogenomic research activities. However, the shortage of skilled professionals is expected to restrict the market growth during the forecast period.
Many older adults (>60%) suffer from two or more chronic conditions. Twin studies have established that genes cause chronic conditions, such as cardiovascular disease (CVDs), diabetes, obesity, RA, Alzheimer's disease (AD), and depression. Using molecular genetic data from genome-wide association studies (GWAS), it is now possible to measure individual-level risks for these chronic diseases. According to the Centers for Disease Control and Prevention (CDC), in 2020, nearly 6 in 10 people in the US suffered from at least one chronic disease, and 4 in 10 people had two or more chronic conditions.
CVDs, such as atherosclerosis, angina pectoris, and acute myocardial infarction, due to a hectic lifestyle result in high mortality rates. As per the data provided by the World Health Organization (WHO), CVDs are the leading cause of death, taking ~17.9 million lives each year. Diabetes is one of the life-threatening diseases with no functional cure. Diabetes of all types can lead to various complications in different parts of the body and increase the risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes. The significant increase in diabetes cases leads to life-changing complications among people. According to the International Diabetes Federation (IDF), in 2017, 46 million diabetic patients were reported in North America, which is expected to reach 62 million by 2045.
The data also reported that ~425 million people had diabetes in 2017, which is expected to reach 629 million by 2045. The disease prevalence will account for a ~35% increase during the forecast period. According to the Alzheimer's Association, in 2020, 55 million people worldwide had Alzheimer's disease. As chronic diseases are increasing quickly, the research on genomics for treating life-threatening illnesses has progressed rapidly over the last five years, driving the market's growth.
Moreover, pharmacogenomics is rapidly transitioning into clinical practice and implementation in healthcare systems supported by government investment totaling over US$ 4 billion in at least 14 countries. These national genomic-medicine initiatives drive transformative change under real-life conditions while simultaneously addressing barriers against implementation and gathering evidence for broader adoption.
In August 2018, Boston Scientific Corporation, a Massachusetts-based company, announced that it landed US$ 4.3 million in seed funding and partnered with Veritas Genetics. With this fund, the company plans to support its mission to enter the era of personal genome sequencing by creating a trusted, secure, and decentralized marketplace for genomic data. Thus, the continuous funding by manufacturers and governments in the genomics field is driving the pharmacogenomics market.
North America Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Mn)
Get more information on this report :
NORTH AMERICA PHARMACOGENOMICS MARKET SEGMENTATION
By Technology
- Hospitals & Clinics
- Biopharmaceutical Companies
- CROs and CDMOs
- Others
By Application
- PCR
- Sequencing
- Microarray
- gel electrophoresis
- mass spectrometry
- Others
By End User
- Drugs Discovery
- Oncology
- Neurological & Psychiatry
- Pain Management
- Cardiovascular
- Others
By Country
- US
- Canada
- Mexico
Company Profiles
- Abbott
- F. HOFFMANN-LA ROCHE LTD.
- Oxford Nanopore Technologies
- THERMO FISHER SCIENTIFIC INC.
- Illumina, Inc.
- QIAGEN
- Agilent Technologies, Inc.
- Myriad Genetics, Inc.
- Admera Healt
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Pharmacogenomics Market – By Technology
1.3.2 North America Pharmacogenomics Market – By Application
1.3.3 North America Pharmacogenomics Market – By End User
1.3.4 North America Pharmacogenomics Market – By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Pharmacogenomics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.3 Experts Opinion
5. Pharmacogenomics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Chronic Diseases
5.1.2 Growing Funding for Pharmacogenomics
5.2 Market Restraints
5.2.1 Lack of Skilled Professionals
5.3 Market Opportunities
5.3.1 Increasing Demand for Third Generation Sequencing
5.4 Future Trends
5.4.1 Increasing Demand for Personalized Medicines
6. Pharmacogenomics Market– North America Analysis
6.1 North America Pharmacogenomics Market Revenue Forecast and Analysis
7. Pharmacogenomics Market Revenue and Forecasts To 2028 – Technology
7.1 Overview
7.2 Pharmacogenomics Market Share by Technology - 2021 & 2028 (%)
7.3 Polymerase Chain Reaction
7.3.1 Overview
7.3.2 Polymerase Chain Reaction: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
7.3.3 Real Time PCR
7.3.3.1 Overview
7.3.3.2 Real Time PCR: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
7.3.4 Standard PCR
7.3.4.1 Overview
7.3.4.2 Standard PCR: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
7.3.5 Digital PCR
7.3.5.1 Overview
7.3.5.2 Digital PCR: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
7.4 Sequencing
7.4.1 Overview
7.4.2 Sequencing: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
7.5 Microarray
7.5.1 Overview
7.5.2 Microarray: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
7.6 Gel Electrophoresis
7.6.1 Overview
7.6.2 Gel Electrophoresis: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
7.7 Mass Spectrometry
7.7.1 Overview
7.7.2 Mass Spectrometry: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
7.8 Others
7.8.1 Overview
7.8.2 Others: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
8. North America Pharmacogenomics Market Revenue and Forecasts To 2028– by Application
8.1 Overview
8.2 Pharmacogenomics Market Share by Application- 2021 & 2028 (%)
8.3 Drug Discovery
8.3.1 Overview
8.3.2 Drug Discovery: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
8.4 Oncology
8.4.1 Overview
8.4.2 Oncology: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
8.5 Neurology & Psychiatry
8.5.1 Overview
8.5.2 Neurology & Psychiatry: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
8.6 Pain Management
8.6.1 Overview
8.6.2 Pain Management: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
8.7 Cardiovascular Disease
8.7.1 Overview
8.7.2 Cardiovascular Disease: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
9. Pharmacogenomics Market Revenue and Forecasts To 2028 – End User
9.1 Overview
9.2 Pharmacogenomics Market Share by End User - 2021 & 2028 (%)
9.3 Hospitals and Clinics
9.3.1 Overview
9.3.2 Hospitals and Clinics: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
9.4 Biopharmaceutical Companies
9.4.1 Overview
9.4.2 Biopharmaceuticals Companies: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
9.5 CROs and CDMOs
9.5.1 Overview
9.5.2 CROs and CDMOs: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
10. Pharmacogenomics Market Revenue and Forecasts to 2028 –Country Analysis
10.1 North America: Pharmacogenomics Market
10.1.1 Overview
10.1.2 North America: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3 North America: Pharmacogenomics Market, by Technology, 2019–2028 (US$ Million)
10.1.3.1 North America: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million)
10.1.4 North America: Pharmacogenomics Market, by Application, 2019–2028 (US$ Million)
10.1.5 North America: Pharmacogenomics Market, by End-User, 2019–2028 (US$ Million)
10.1.6 North America: Pharmacogenomics Market, by Country, 2021 & 2028 (%)
10.1.6.1 US: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.6.1.1 Overview
10.1.6.1.2 US: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.6.1.3 US: Pharmacogenomics Market, by Technology, 2019–2028 (US$ Million)
10.1.6.1.3.1 US: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million)
10.1.6.1.4 US: Pharmacogenomics Market, by Application, 2019–2028 (US$ Million)
10.1.6.1.5 US: Pharmacogenomics Market, by End-User, 2019–2028 (US$ Million)
10.1.6.2 Canada: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.6.2.1 Overview
10.1.6.2.2 Canada: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.6.2.3 Canada: Pharmacogenomics Market, by Technology, 2019–2028 (US$ Million)
10.1.6.2.3.1 Canada: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million)
10.1.6.2.4 Canada: Pharmacogenomics Market, by Application, 2019–2028 (US$ Million)
10.1.6.2.5 Canada: Pharmacogenomics Market, by End-User, 2019–2028 (US$ Million)
10.1.6.3 Mexico: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.6.3.1 Overview
10.1.6.3.2 Mexico: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.6.3.3 Mexico: Pharmacogenomics Market, by Technology, 2019–2028 (US$ Million)
10.1.6.3.3.1 Mexico: Pharmacogenomics Market, by PCR, 2019–2028 (US$ Million)
10.1.6.3.4 Mexico: Pharmacogenomics Market, by Application, 2019–2028 (US$ Million)
10.1.6.3.5 Mexico: Pharmacogenomics Market, by End-User, 2019–2028 (US$ Million)
11. Impact of COVID-19 Pandemic on North America Pharmacogenomics Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
12. Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview
13. Company Profiles
13.1 Abbott
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 F. HOFFMANN-LA ROCHE LTD.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Oxford Nanopore Technologies
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 THERMO FISHER SCIENTIFIC INC.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Illumina, Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 QIAGEN
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Agilent Technologies, Inc.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Myriad Genetics, Inc.
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Admera Health
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Dynamic DNA Laboratories
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 2. North America: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million)
Table 3. North America Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 4. US Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 5. US Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million)
Table 6. US Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 7. US Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
Table 8. Canada: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 9. Canada: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million)
Table 10. Canada Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 11. Canada Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
Table 12. Mexico: Pharmacogenomics Market, by Technology – Revenue and Forecast to 2028 (US$ Million)
Table 13. Mexico: Pharmacogenomics Market, by PCR– Revenue and Forecast to 2028 (US$ Million)
Table 14. Mexico Pharmacogenomics Market, by Application– Revenue and Forecast to 2028 (US$ Million)
Table 15. Mexico Pharmacogenomics Market, by End-User – Revenue and Forecast to 2028 (US$ Million)
Table 16. Organic Developments Done By Companies
Table 17. Inorganic Developments Done By Companies
Table 18. Glossary of Terms
LIST OF FIGURES
Figure 1. Pharmacogenomics Market Segmentation
Figure 2. Pharmacogenomics Market, By Country
Figure 3. North America Pharmacogenomics Market Overview
Figure 4. PCR Segment Held Largest Share of Technology Segment in Pharmacogenomics Market
Figure 5. North America Pharmacogenomics Market- Leading Country Markets (US$ Million)
Figure 6. North America: PEST Analysis
Figure 7. Experts Opinion
Figure 8. North America Pharmacogenomics Market– Revenue Forecast and Analysis – 2021 - 2028
Figure 9. Pharmacogenomics Market Share by Segment - 2021 & 2028 (%)
Figure 10. Polymerase Chain Reaction: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 11. Real Time PCR: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 12. Standard PCR: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 13. Digital PCR: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 14. Sequencing: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 15. Microarray: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 16. Gel Electrophoresis: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 17. Mass Spectrometry: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 18. Others: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 19. Pharmacogenomics Market Share by Application- 2021 & 2028 (%)
Figure 20. Drug Discovery: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 21. Oncology: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 22. Neurology & Psychiatry: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 23. Pain Management: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 24. Cardiovascular Disease: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 25. Others: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 26. Pharmacogenomics Market Share by End User - 2021 & 2028 (%)
Figure 27. Hospital and Clinics: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 28. Biopharmaceutical Companies: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 29. CROs and CDMOs: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 30. Others: Pharmacogenomics Market Revenue and Forecasts To 2028 (US$ Million)
Figure 31. North America: Pharmacogenomics Market, by Key Country – Revenue (2021) (US$ Million)
Figure 32. North America Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Million)
Figure 33. North America: Pharmacogenomics Market, by Country, 2021 & 2028 (%)
Figure 34. US: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Canada: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. Mexico: Pharmacogenomics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. Impact of COVID-19 Pandemic in North America Country Markets
- Abbott
- F. HOFFMANN-LA ROCHE LTD.
- Oxford Nanopore Technologies
- THERMO FISHER SCIENTIFIC INC.
- Illumina, Inc.
- QIAGEN
- Agilent Technologies, Inc.
- Myriad Genetics, Inc.
- Admera Health
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America pharmacogenomics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America pharmacogenomics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.